Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 1/20 | 0.53 |
| ▸ | PIK3CG | P48736 | 3/20 | 0.50 |
| ▸ | NOS1 | P29475 | 1/20 | 0.47 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.45 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.45 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30965441 | 1.00 | ADORA2A (0.53) | ADORA2APIK3CGNOS1PIK3CAPIK3CB | |
| Bromide SCHEMBL11633687 | 0.98 | ADORA2A (0.52) | ADORA2APIK3CGNOS1PIK3CAPIK3CB | |
| SCHEMBL12843982 | 0.84 | ADORA1 (0.40) | ADORA2APIK3CGNOS1PIK3CAPIK3CB | |
| SCHEMBL6239850 | 0.81 | PIK3CG (0.41) | ADORA2APIK3CGNOS1PIK3CAPIK3CB | |
| SCHEMBL3692533 | 0.79 | ADORA2A (0.57) | ADORA2APIK3CGNOS1PIK3CAPIK3CB | |
| SCHEMBL5514814 | 0.78 | NOS1 (0.62) | ADORA2ANOS1 | |
| SCHEMBL3537607 | 0.78 | ADORA2A (0.55) | ADORA2APIK3CGNOS1PIK3CAPIK3CB | |
| SCHEMBL3660280 | 0.76 | ADORA2A (0.53) | ADORA2APIK3CGNOS1PIK3CAPIK3CB | |
| SCHEMBL8813993 | 0.76 | NOS1 (0.61) | NOS1 | |
| SCHEMBL12430387 | 0.76 | ADORA2A (0.48) | ADORA2APIK3CGNOS1PIK3CAPIK3CB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100305134-A1 | SPECIFIC INHIBITORS OF PTERIDINE REDUCTASE WITH ANTIPARASITIC ACTION | TYDOCK PHARMA S.R.L. (IT) | 2010-12-02 | — | — | US | claimed |
| EP-2234998-A2 | SPECIFIC INHIBITORS OF PTERIDINE REDUCTASE WITH ANTIPARASITIC ACTION | Tydock Pharma S.r.l. (IT) | 2010-10-06 | — | — | EP | claimed |
| WO-2009080367-A2 | SPECIFIC INHIBITORS OF PTERIDINE REDUCTASE WITH ANTIPARASITIC ACTION | TYDOCKPHARMA S.R.L. (IT) | 2009-07-02 | — | — | WO | claimed |
| US-4224446-A | Process for the production of methotrexate | LONZA LTD. (CH) | 1980-09-23 | — | — | US | claimed |
| CN-118330110-A | Method for determining 2, 4-diamino-7-chloromethyl pteridine | 重庆药友制药有限责任公司 | 2024-07-12 | — | — | CN | disclosed |
| US-20230226214-A1 | BIFUNCTIONAL BRIDGING COMPOSITIONS FOR VIRAL TRANSDUCTION | LYCIA THERAPEUTICS, INC. | 2023-07-20 | — | — | US | disclosed |
| WO-2022272307-A1 | BIFUNCTIONAL FOLATE RECEPTOR BINDING COMPOUNDS | LYCIA THERAPEUTICS, INC. (US) | 2022-12-29 | — | — | WO | disclosed |
| WO-2022150721-A1 | BIFUNCTIONAL FOLATE RECEPTOR BINDING COMPOUNDS | LYCIA THERAPEUTICS, INC. (US) | 2022-07-14 | — | — | WO | disclosed |
| EP-2797417-B1 | SELECTIVE INHIBITION OF PHOSPHOENOLPYRUVATE CARBOXYLASES OF C4 PLANTS | HEINRICH HEINE UNIV DUESSELDORF (DE) | 2019-07-31 | — | — | EP | disclosed |
| US-9867828-B2 | Aminopterin dosage forms | AMINOPTERIN LLC (US) | 2018-01-16 | — | — | US | disclosed |
| EP-1855682-B1 | AMINOPTERIN DOSAGE FORMS FOR INFLAMMATORY DISORDERS | AMINOPTERIN LLC (US) | 2017-11-01 | — | — | EP | disclosed |
| EP-2707487-B1 | RIBOSWITCHES | UNIV MANCHESTER (GB) | 2017-10-04 | — | — | EP | disclosed |
| US-20050209239-A1 | Compositions and methods employing aminopterin | AMINOPTERIN LLC | 2005-09-22 | — | — | US | disclosed |
| CN-1439641-A | Anti-cancer chemicals of methotrexate derivatives and their uses in pharmaceutical science | CHINESE PHARMACEUTICAL UNIV (CN) | 2003-09-03 | — | — | CN | disclosed |
| US-4306064-A | Synthesis of 2,4-diamino-6-hydroxymethylpteridine | MONSANTO RESEARCH CORPORATION | 1981-12-15 | — | — | US | disclosed |
| US-4224446-A | Process for the production of methotrexate | LONZA LTD. (CH) | 1980-09-23 | — | — | US | disclosed |
| US-4224446-A | Process for the production of methotrexate | LONZA LTD. (CH) | 1980-09-23 | — | — | US | disclosed |
| US-4079056-A | REACTING 2,4-DIAMINO-6-PTERIDINE-METHANOL-HBR WITH TRIPHENYLPHOSPHINE DIBROMIDE OR PHOSPHORUS TRIBROMIDE | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH, EDUCATION AND WELFARE (US) | 1978-03-14 | — | — | US | disclosed |
| US-4077957-A | INTERMEDIATE FOR METHOTREXATE | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH, EDUCATION AND WELFARE (US) | 1978-03-07 | — | — | US | disclosed |
| US-3989703-A | Process of preparing N[p-{[(2,4-diamino-6-pteridyl)-methyl]N10 -methylamino}-benzoyl]-glutamic acid | INSTITUTUL ONCOLOGIC (RU) | 1976-11-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100305134-A1 | SPECIFIC INHIBITORS OF PTERIDINE REDUCTASE WITH ANTIPARASITIC ACTION | QDPR, DHFR, DDC | ADORA2A 1687/4885PIK3CG 3307/4885NOS1 1167/4885 |
| US-20230226214-A1 | BIFUNCTIONAL BRIDGING COMPOSITIONS FOR VIRAL TRANSDUCTION | HAVCR2, FCGR3B, FCGR2A | ADORA2A 637/4885PIK3CG 1942/4885NOS1 4318/4885 |
| US-20050209239-A1 | Compositions and methods employing aminopterin | SLC7A1, AADAT, SLC19A1 | ADORA2A 964/4885PIK3CG 4270/4885NOS1 633/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.